Healthcare
Live Price
Offline$0.00001
+0.00% today
1Y Change
+0.00%
Window
Jun 20, 2025 → Jun 16, 2026
Coverage: 249 bars · Jun 20, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
RVL Pharmaceuticals plc (RVLPQ) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 20, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of +184.1%, EPS growth of +39.6%, a dividend yield of 0.0%. What stands out right now is revenue +184.1%, EPS +39.6%, free cash flow +31.8% with operating margin -91.9% and ROIC -41.3%. Valuation is more restrained than many high-expectation growth names at price/sales 0.1. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines RVLPQ price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RVLPQ
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RVLPQ Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RVLPQ and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$263.7M
+9.9% YoY
FY Net Income
-$109.7M
+59.5% YoY
Free Cash Flow
$33.4M
+13.2% YoY
Revenue Growth
+184.1%
EPS Growth
+39.6%
Gross Margin
81.0%
Net Margin
-104.0%
Income statement
USD
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 50M | 18M | 28M | 240M | 264M |
| Gross Profit | 40M | 14M | 24M | 128M | 122M |
| Operating Income | -59M | -79M | -62M | -281M | 6M |
| EBITDA | -48M | -71M | -70M | -223M | -16M |
| Net Income | -52M | -65M | -80M | -271M | -110M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Cash & Equivalents | 45M | 40M | 114M | 96M | 71M |
| Total Assets | 129M | 145M | 371M | 463M | 827M |
| Total Liabilities | 77M | 68M | 277M | 349M | 443M |
| Shareholder Equity | 51M | 77M | 94M | 115M | 384M |
| Total Debt | 57M | 48M | 222M | 273M | 269M |
| Net Debt | 13M | 7M | 108M | 177M | 198M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
38M
+11.9% YoY
Capital Expenditures
4M
-2.7% YoY
Free Cash Flow
33M
+13.2% YoY
Key ratios
Gross Margin
81.0%
Operating Margin
-91.9%
Net Margin
-104.0%
ROE
-80.9%
Debt / Equity
1.13x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.